Home > Oncology > ASCO 2020 > Lung Cancer > Adjuvant osimertinib in NSCLC: practice changing ADAURA trial

Adjuvant osimertinib in NSCLC: practice changing ADAURA trial

Presented By
Prof. Roy S. Herbst, Yale Cancer Center, USA
ASCO 2020
Phase 3, ADAURA
Featured video: Phase III study assessing the efficacy of adjuvant use of targeted agent osimertinib in patients with localized non-small-cell lung cancer and EGFR mutation after complete tumor resection and adjuvant chemotherapy. Adjuvant osimertinib demonstrated a statistically significant and clinically meaningful benefit for patients with stage IB, II, or IIIA EGFR-mutant non-small cell lung cancer (NSCLC) with complete tumour resection in the phase 3 ADAURA trial, presented by Prof. Roy Herbst (Yale Cancer Center, USA) [1]. Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with demonstrated efficacy as a frontline agent for metastatic NSCLC with co...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on